A Phase 2 interventional study of Immune Globulin Intravenous (Human) in Immunologic Deficiency Syndrome, sponsored by Grifols Therapeutics LLC. Completed at 8 sites in 2 countries. Open to participants aged 13 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-20.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Immunologic Deficiency Syndromes with a site in United States — 27 open to participants now, 34 under way, none of them phase 3. Immunologic Deficiency Syndromes · United States.
Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, this one is the 30th largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2006, is one of 27 in phase 2, and was the 32nd registered.
204 studies on the registry are indexed under Immunologic Deficiency Syndromes; 50 are open to participants now.
Browse Immunologic Deficiency Syndromes studies →27 of the 127 studies in Immunologic Deficiency Syndromes with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1–120 · Healthy volunteers
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 4+
Monica Bhatia · Sites in United States
Ages 3 mo–26 yrs
Children's Hospital of Philadelphia · Sites in United States
Ages 1 mo–25 yrs
Washington University School of Medicine · Sites in United States
Ages 8+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger; 30 take children under 18; 10 take healthy volunteers.
This study: 13 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 40 · Phase 3 10 · Phase 4 2
First in 1977; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is above the median of 30 across 123 interventional studies indexed under Immunologic Deficiency Syndromes.
Median enrollment 28 across the 77 interventional studies, 142 across the 45 observational. Of the 83 that completed or were terminated, 28 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 3 studies filed under Immunologic Deficiency Syndromes — fewer than ten, so there is no comparison to draw.
9 of the studies in Immunologic Deficiency Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02356653Children's Hospital of PhiladelphiaExpanded Access Protocol Using CD3+/CD19+ Depleted PBSC | 2027-01 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT05333471National Institute of Allergy and Infectious Diseases (NIAID)Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis | 2027-03-01 |
| NCT04554914Pierre Fabre MedicamentA Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | 2027-06 |
| NCT01666080Masonic Cancer Center, University of MinnesotaSecond or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare the blood level of Gamunex in patients. Patients will take it as an injection under the skin or in a vein. The study will compare how safe and tolerable the two methods are in the patients. The patients in this study have a defect in their immune system from a genetic cause.
This is an open-label, single-sequence, multi-center trial with subjects previously diagnosed with primary immune deficiency. Subjects will be on IGIV until a steady state is reached at which time PK profiling during the IV phase will occur. Subjects will begin SC administration 1 week following last IV dose and followed for a period of six months. PK profiling in SC phase will occur when subject reaches approximate steady-state on SC administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
Biological: Immune Globulin Intravenous (Human)
This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
Also known as: Gamunex, Gaminex, Immune globulin intravenous (Human)(IGIV), BAY 41-1000, TAL-05-00004, IGIV-C, IVIG, IGIVnex, NDC-13353-645-71, NDC-13353-646-24, NDC-13353-645-12, NDC-13353-645-15, NDC-13353-645-2
Geometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG)
Geometric least-squares mean of steady-state plasma concentration of total IgG vs. time profile (AUC).
Time frame: IV Phase (21 or 28 days) at IV Visit #1, pre- and post-dose: 0 hr., 1 hr., and 1, 2, 3, 5, 7, 14, 21, and 28 days; SC Phase at Week #17, pre- and post-dose: 0 hr., and 1, 3, 4, 5, and 7 days
First Patient, First Visit: Nov. 21, 2006, Last patient, Last visit: Aug. 26, 2008. This study was performed at medical clinics.
| Milestone | IGIV-C |
|---|---|
| Started | 21 |
| Completed | 18 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | IGIV-C |
|---|---|
| Started | 32 |
| Completed | 32 |
| Not completed | 0 |
| Milestone | IGIV-C |
|---|---|
| Started | 32 |
| Completed | 25 |
| Not completed | 7 |
| Withdrew: Adverse event | 2 |
| Withdrew: Non-compliance with study medication | 2 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Lost to follow-up | 1 |
Geometric least-squares mean of steady-state plasma concentration of total IgG vs. time profile (AUC).
| mg*hr/ml | Gamunex Intravenous (IV) Administration | Gamunex Subcutaneous (SC) Administration |
|---|---|---|
| Geometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG) | 7549 ± 1217 | 6706 ± 1241 |
Collected over Run-in phase (if required): 3 - 4 months; Intravenous Phase: 4 - 5 weeks; Subcutaneous Phase: 24 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-In Phase | — | 2/21 (9.5%) | 11/21 (52.4%) |
| Intravenous Phase | — | 0/32 (0%) | 9/32 (28.1%) |
| Subcutaneous Phase | — | 1/32 (3.1%) | 29/32 (90.6%) |
| Event | Run-In Phase | Intravenous Phase | Subcutaneous Phase |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/21 | 0/32 | 0/32 |
| Sepsis syndromeInfections and infestations | 1/21 | 0/32 | 0/32 |
| Incisional herniaInjury, poisoning and procedural complications | 1/21 | 0/32 | 0/32 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/21 | 0/32 | 0/32 |
| Drug dependencePsychiatric disorders | 0/21 | 0/32 | 1/32 |
| Event | Run-In Phase | Intravenous Phase | Subcutaneous Phase |
|---|---|---|---|
| Infusion site erythemaGeneral disorders | 0/21 | 0/32 | 13/32 |
| Infusion site painGeneral disorders | 0/21 | 0/32 | 13/32 |
| Infusion site swellingGeneral disorders | 0/21 | 0/32 | 11/32 |
| SinusitisInfections and infestations | 2/21 | 0/32 | 8/32 |
| Infusion site extravasationGeneral disorders | 0/21 | 0/32 | 8/32 |
| Infusion site pruritusGeneral disorders | 0/21 | 0/32 | 8/32 |
| Upper respiratory tract infectionInfections and infestations | 1/21 | 2/32 | 7/32 |
| Infusion site bruisingGeneral disorders | 0/21 | 0/32 | 7/32 |
| HeadacheNervous system disorders | 4/21 | 1/32 | 6/32 |
| DiarrhoeaGastrointestinal disorders | 0/21 | 2/32 | 5/32 |
| Age, Categorical(Participants) | Safety Population |
|---|---|
| <=18 years | 3 |
| Between 18 and 65 years | 28 |
| >=65 years | 4 |
| Age, Continuous(years) | Safety Population |
|---|---|
| Mean | 42.5 ± 15.8 |
| Sex: Female, Male(Participants) | Safety Population |
|---|---|
| Female | 28 |
| Male | 7 |
| Region of Enrollment(participants) | Safety Population |
|---|---|
| United States | 26 |
| Canada | 9 |
The record gives a start of Nov 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Immunologic Deficiency Syndromes →